Motexafin gadolinium
From Self-sufficiency
| File:Motexafin gadolinium 3D sticks.png | |
| Identifiers | |
|---|---|
| CAS Number | 156436-89-4 |
| ATC code | none |
| PubChem | CID 158385 |
| Chemical data | |
| Formula | C52H72GdN5O14 |
| Molar mass | 1148.403 g/mol[[Script error: No such module "String".]] |
Motexafin gadolinium (proposed tradename Xcytrin) is an inhibitor of thioredoxin reductase and ribonucleotide reductase. It has been proposed as a possible chemotherapeutic agent in the treatment of brain cancer.[1]
History
On May 9, 2006, a New Drug Application was submitted to the United States Food and Drug Administration (FDA) by Pharmacyclics, Inc.[2]
On December 2007, the FDA issued a not approvable letter for motexafin gadolinium.[3]
References
- ↑ Richards G, Mehta M (2007). "Motexafin gadolinium in the treatment of brain metastases". Expert opinion on pharmacotherapy. 8 (3): 351–9. doi:10.1517/14656566.8.3.351. PMID 17266469.
- ↑ Pharmacyclics, Inc. press release - Pharmacyclics to Submit New Drug Application for Xcytrin for Treatment of Lung Cancer Patients With Brain Metastases
- ↑ Pharmacyclics, Inc. press release - Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
| 40px | This biochemistry article is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Gadolinium compounds
- Biochemistry stubs
- 2Fix
